MHB018A Treatment in Patients With Active Thyroid Eye Disease

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED.
Epistemonikos ID: 5310a3cf96d09c423ec6a54e91cbd88f3f746cc6
First added on: Jun 01, 2025